

Yescarta

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do not call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:	Date:
Patient's ID:	
Physician's Name:	
Specialty:	NPI#:
Physician Office Telephone:	Physician Office Fax:
Referring Provider Info: 🛭 Same as Rec	questing Provider
Name:	NPI#:
Fax:	Phone:
Rendering Provider Info: 🗆 Same as Re	ferring Provider 🗆 Same as Requesting Provider
Name:	- ·
Fax:	Phone:
• •	ndia, and/or evidence-based practice guidelines.
Required Demographic Information:	
Patient Weight:	kg
PatientHeight:	cm
	tm

<u>Cr</u> 1.	what is the diagnosis?	
	☐ Diffuse large B-cell lymphoma (DLBCL) arising from follicular lymphoma (also known as histologic transformation of follicular lymphoma to DLBCL)	
	☐ Histologic transformation of nodal marginal zone lymphoma to DLBCL	
	☐ Diffuse large B-cell lymphoma ☐ Primary mediastinal large B-cell lymphoma	
	☐ High-grade B-cell lymphoma (high-grade B-cell lymphoma with translocations of MYC and BCL2 and/or BCL6 [double/triple hit lymphoma], high-grade B-cell lymphoma, not otherwise specified) ☐ Acquired immunodeficiency syndrome (AIDS)-related B-cell lymphomas (including AIDS-related diffuse large B-cell lymphoma, primary effusion lymphoma, and human herpesvirus 8 (HHV8)-positive diffuse large B-cell lymphoma, not otherwise specific) ☐ Monomorphic post-transplant lymphoproliferative disorder (B-cell type) ☐ Other	
2.	What is the ICD-10 code?	
3.	Has the patient previously received one complete treatment course of Yes carta or another CD19-directed chimeric antigen receptor (CAR) T-cell therapy (e.g., Kymriah)? ☐ Yes ☐ No	
4.	Does the patient have primary central nervous systemly mphoma?	
5.	Does the patient have CD19 positive disease that was confirmed by testing or analysis? ACTION REQUIRED: If Yes, attach results of testing or analysis confirming CD19 protein on the surface of the B-cell. Yes No Unknown	
Co	emplete the following section based on the patient's diagnosis, if applicable.	
	ction A: Diffuse large B-cell lymphoma (DLBCL) arising from follicular lymphoma (also known as histologic nsformation of follicular lymphoma to DLBCL) and histologic transformation of nodal marginal zone lymphoma to	
<u>DL</u> 6.	BCL How many prior chemoimmunotherapy regimens has the patient received? regimens	
7.	Did at least one prior chemoimmunotherapy regimen received by the patient include an anthracycline or anthracenedione-based regimen? <i>If Yes, skip to Section B</i> ☐ Yes, anthracycline-based regimen ☐ Yes, anthracenedione-based regimen ☐ No	
8.	Are anthracycline and anthracenedione-based regimens contraindicated for the patient? \square Yes \square No Skip to Section B	
	ction B: All Other B-Cell Lymphoma Subtypes and common requirements Will Yescarta be used as subsequent treatment for the disease? ☐ Yes ☐ No	
I a	attest that this information is accurate and true, and that documentation supporting this	
	formation is available for review if requested by CVS Caremark or the benefit plan sponsor.	
Χ_		
۲r	escriber or Authorized Signature Date (mm/dd/yy)	

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720 Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If yo u have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Yescarta SGM-102020.